MétaCan
Menu
← Back to cohort
Record W4416084782 · doi:10.1093/neuonc/noaf201.0127

BIOM-39. PLASMA PROTEOMICS REVEAL KEY PRELIMINARY BIOMARKERS FOR GLIOBLASTOMA PROGRESSION AND DIFFERENTIAL DIAGNOSIS

2025· article· en· W4416084782 on OpenAlexaff
Miyo K. Chatanaka, Andrew Ajisebutu, Leonardo de Macêdo Filho, Lisa Avery, Nicholas Mikolajewicz, Mingyue Wang, Catherine Demos, Jermaine Brown, Taron Gorham, Salvia Misaghian, Nikhil Padmanabhan, Hans Layman, Daniel Romero, Martin Stengelin, Anu Mathew, George B. Sigal, Jacob N. Wohlstadter, Craig Horbinski, Gelareh Zadeh, Eleftherios P. Diamandis, Alireza Mansouri

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsSinai Health SystemHospital for Sick ChildrenUniversity Health NetworkUniversity of Toronto
Fundersnot available
KeywordsGlioblastomaReceiver operating characteristicProteomicsDifferential diagnosisDiseaseBrain tumorRandom forest

Abstract

fetched live from OpenAlex

Abstract Adult-type diffuse gliomas, including glioblastoma (GBM), astrocytoma, and oligodendroglioma, are among the most aggressive brain tumors, often exhibiting poor prognosis. Diagnosis currently relies on MRI and biopsy, but for individuals ineligible for resection, non-invasive diagnostic tools are lacking. Additionally, distinguishing primary from recurrent disease and monitoring therapy response remain critical unmet needs. We evaluated seven candidate proteomic markers in plasma from individuals with GBM (n=143), astrocytoma (n=50), oligodendroglioma (n=32), and non-tumor controls (n=30) using research-use-only electrochemiluminescence assays (Meso Scale Discovery). Key questions included: (1) Do protein levels change between primary and recurrent GBM? (2) Do protein concentrations correlate with survival in primary vs. recurrent disease? (3) Can markers predict GBM tumor burden? (4) Can they distinguish GBM from other gliomas and controls? The results showed that neurofilament light chain (NEFL) increased significantly from primary to recurrent GBM (unadjusted p = 0.008). In primary GBM, low fatty acid binding protein 4 (FABP4) correlated with survival (adjusted p = 0.028), but no significance was observed in recurrent disease after adjustment. Machine learning (Lasso regression) showed poor performance in predicting tumor volume (cross-validated R² = 0.192). However, dimensionality reduction (PCA-UMAP) revealed distinct clustering of GBM samples versus astrocytomas, oligodendrogliomas, and controls. A random forest classifier trained on a 70:30 split achieved strong diagnostic performance (test AUC = 0.96, sensitivity = 0.95, specificity = 0.83). To conclude, plasma proteomic markers, particularly NEFL and FABP4, show promise for monitoring recurrence and prognostic stratification in GBM. While tumor volume prediction was unreliable, machine learning models excelled in differentiating GBM from other gliomas and controls, suggesting clinical utility for non-invasive diagnosis. Further validation is warranted to refine biomarker panels for precision oncology applications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.309
Teacher spread0.294 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicGlioma Diagnosis and Treatment→French-language works237,207→